Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation

Leeuwen, Marina T. van; Grulich, Andrew E.; Webster, Angela C; McCredie, Margaret; Stewart, John H.; McDonald, S.; Amin, Janaki; Kaldor, John; Chapman, Jeremy R.; Vajdic, Claire M.

doi:10.1182/blood-2009-02-202507

Cited by 122 publications

(109 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Trasplante multivisceral > intestino > pulmón > corazón/pulmón > corazón > riñón Presencia de malignidades pretrasplante La incidencia de ELPT tiene una distribución bimodal, con un pico temprano (primeros dos años postrasplante), y uno tardío, con diferencias en los factores de riesgo y los hallazgos histológicos, lo que sugiere mecanismos diferentes para su producción. Los casos tempranos parecen ser mediados principalmente por la infección con VEB en el contexto de la inmunosupresión profunda, y los tardíos se relacionan con la inmunosupresión prolongada, la edad avanzada y probablemente la exposición a agentes específicos, lo cual se ha evidenciado en diferentes estudios (5)(6)(7)(8).…”

Section: Incidencia Y Factores De Riesgounclassified

Enfermedad linfoproliferativa postrasplante de órgano sólido

Nieto-Ríos

Ríos

Higuita

et al. 2016

iatreia

View full text Add to dashboard Cite

RESUMENCon la denominación enfermedad linfoproliferativa postrasplante (ELPT) se conoce un grupo de trastornos que se pueden presentar con posterioridad al trasplante de órganos sólidos, con incidencia variable dependiendo del tipo de órgano trasplantado. La presentación clínica inespecífica de esta enfermedad, el compromiso extranodal y su amplio espectro histopatológico hacen que tanto la clasificación como el tratamiento sean complejos. Esta revisión presenta una actualización sobre la ELPT en pacientes con trasplante de órgano sólido. PALABRAS CLAVE Infecciones por Virus de Epstein-Barr; Trasplante de Órganos; Trastornos Linfoproliferativos SUMMARY Post-transplant lymphoproliferative diseasePost-transplant lymphoproliferative disease (PTLD) is a group of disorders that may occur after transplantation. Its incidence is variable according to the transplanted organ. The clinical variability of this disease, its extra-nodal involvement and its broad histopathological spectrum make both classification and management very complex. This review provides an update about PTLD in patients with solid organ transplantation.

show abstract

Section: Incidencia Y Factores De Riesgounclassified

Enfermedad linfoproliferativa postrasplante de órgano sólido

Nieto-Ríos

Ríos

Higuita

et al. 2016

iatreia

View full text Add to dashboard Cite

show abstract

“…9 CNI, especially tacrolimus, increase the risk of posttransplant lymphoproliferative disease (PTLD) versus recipients without CNI exposure. 3 CNI inhibit T-cell activation including that of EBV-specific CD8 þ T cells. 10 In light of the findings by Chaigne-Delalande et al, magnesium deficiency and decreased expression of NKG2D are possibly at play here.…”

Section: Clinical Support For a Role Of Magnesium Status In The Develmentioning

confidence: 99%

Magnesium and lymphoma: opportunities in translation

2014

View full text Add to dashboard Cite

“…In addition to Epstein-Barr virus status of the recipient, induction therapy has been shown to be a risk factor for early posttransplant lymphoproliferative disease using OKT3, antithymocyte globulins, 16 and alemtuzumab, 17 although it is not clear if there is a difference between these agents.…”

Section: Role Of Specific Immunosuppressantsmentioning

confidence: 99%

Donor-Transmitted, Donor-Derived, and De Novo Cancer After Liver Transplant

Chapman¹,

Lynch²

2014

Exp Clin Transplant

Self Cite

View full text Add to dashboard Cite

Cancer is the third most common cause of death (after cardiovascular disease and infection) for patients who have a functioning kidney allograft. Kidney and liver transplant recipients have similar cancer risks because of immunosuppression but different risks because of differences in primary diseases that cause renal and hepatic failure and the inherent behavior of cancers in the liver. There are 4 types of cancer that may develop in liver allograft recipients: (1) recurrent cancer, (2) donor-transmitted cancer, (3) donor-derived cancer, and (4) de novo cancer. Identification of potential donor cancer transmission may occur at postmortem examination of a deceased donor or when a probable donortransmitted cancer is identified in another recipient. Donor-transmitted cancer after liver transplant is rare in Australia, the United Kingdom, and the United States. Aging of the donor pool may increase the risk of subclinical cancer in donors. Liver transplant recipients have a greater risk of de novo cancer than the general population, and risk factors for de novo cancer in liver transplant recipients include primary sclerosing cholangitis, alcoholic liver disease, smoking, and increased age. Liver transplant recipients may benefit from cancer screening because they have a high risk, are clearly identifiable, and are under continuous medical supervision.

show abstract

Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation

Cited by 122 publications

References 40 publications

Enfermedad linfoproliferativa postrasplante de órgano sólido

Enfermedad linfoproliferativa postrasplante de órgano sólido

Magnesium and lymphoma: opportunities in translation

Donor-Transmitted, Donor-Derived, and De Novo Cancer After Liver Transplant

Contact Info

Product

Resources

About